Targeted alpha therapy employs alpha-emitting radionuclides in conjunction with tumor-targeting vectors to eradicate cancer cells with alpha radiation. A key component of these radiopharmaceutical agents is the bifunctional chelating agent, a ligand that stably retains and attaches the alpha-emitting nuclide to the targeting vector. The development of bifunctional chelating agents for alpha therapy nuclides is hindered by their unusual coordination chemistry and the limited availability of these elements. In this presentation, we describe our efforts to develop new chelating agents for alpha therapy nuclides. This work highlights the novel ligand design strategies and challenges faced in designing new ligands for these nuclides.  <br/>

Ligand design for alpha therapy nuclides

256th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.